Important note: Information in this article was accurate in 2008. The state of the art may have changed since the publication date.
Bangkok Post - January 15, 2008
Apiradee Treerutkuarkul
Public Health Minister Mongkol Na Songkhla yesterday said Indian-made cancer drug docetaxel had passed the registration process with the FDA. He did not disclose the generic maker, but said the process would help fast-track the import of the drug for use if the policy to bypass the patent of the drug is needed for the original version.
Sanofi-Aventis owns the patent of this medicine commonly used to treat breast cancer.
Speaking after visiting cancer drug manufacturers in India, Dr Mongkol said the ministry would import the cancer drug and use it for treating patients under the universal healthcare scheme only.
He conceded that it may be impossible to derive the knowledge of how to make the cancer drug for use in the country because the research and development needed was too complicated for local industry.
The National Health Security Office, which oversees the universal healthcare scheme for 48 million people, last September asked the Public Health Ministry to consider overriding the patents of four cancer drugs - imatinib, letrozole, docetaxel, and erlotinibas - because they are too expensive for local people.
However, the government revoked a decision to bypass the patent on imatinib after both the state and patent owner Novartis agreed to provide free medication for 900 patients under the universal healthcare scheme.
FDA secretary-general Siriwat Tiptaradol said he would have to negotiate the price of the cancer medicine with the Indian drug maker before importing the drug for local use.
The cost of the generic version of docetaxel is 4,000 baht per 80mg dose.
The retail price of erlotinibas is 2,800-3,000 baht per tablet compared with the generic version, which costs between 275-735 per tablet.
Letrozole, meanwhile, costs about 230 baht per tablet, but its generic version is priced at only 7-10 baht.
The Thai government angered some of the world's biggest pharmaceutical firms by announcing compulsory licensing for the Aids drugs Efavirenz and Kaletra along with the heart drug Plavix last year.
Compulsory licensing is allowed by the World Trade Organisation in the case of a national emergency. This lets the government bypass drug patents and import or produce generic versions of patented drugs for non-commercial purposes.
080115
BP080101
Copyright © 2008 - The Bangkok Post. Reproduction of this article (other than one copy for personal reference) must be cleared through the Bangkok Post.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .